This systematic review was conducted to determine factors that are associated with the degree of hypertrophy of the future liver remnant following portal vein embolization. An extensive search on September 15, 2020, and subsequent literature screening resulted in the inclusion of forty-eight articles with 3368 patients in qualitative analysis, of which 18 studies were included in quantitative synthesis. Meta-analyses based on a limited number of studies showed an increase in hypertrophy response when additional embolization of segment 4 was performed (pooled difference of medians = − 3.47, 95% CI − 5.51 to − 1.43) and the use of N-butyl cyanoacrylate for portal vein embolization induced more hypertrophy than polyvinyl alcohol (pooled standardized mean difference (SMD) = 0.60, 95% CI 0.30 to 0.91). There was no indication of a difference in degree of hypertrophy between patients who received neo-adjuvant chemotherapy and those who did not receive pre-procedural systemic therapy

(pooled SMD = − 0.37, 95% CI − 1.35 to 0.61), or between male and female patients (pooled SMD = 0.19, 95% CI − 0.12 to 0.50).

The study was registered in the International Prospective Register of Systematic Reviews on April 28, 2020 (CRD42020175708).

这项系统评价旨在确定与门静脉栓塞后未来残肝肥大程度相关的因素。2020 年 9 月 15 日的广泛搜索和随后的文献筛选结果将 48 篇文章纳入了 3368 名患者的定性分析，其中 18 项研究纳入了定量综合。基于有限数量研究的荟萃分析显示，当对第 4 段进行额外栓塞（中位数的汇总差异 = - 3.47, 95% CI - 5.51 至 - 1.43）和使用氰基丙烯酸正丁酯时，肥大反应增加门静脉栓塞比聚乙烯醇引起更多的肥大（合并标准化平均差 (SMD) = 0.60, 95% CI 0.30 至 0.91）。

（合并 SMD = - 0.37, 95% CI - 1.35 至 0.61）或男性和女性患者之间（合并 SMD = 0.19, 95% CI - 0.12 至 0.50）。

该研究于 2020 年 4 月 28 日在国际系统评价前瞻性登记册中注册（CRD42020175708）。